Resistance Training in Relapsing-Remitting Multiple Sclerosis

被引：1
|
作者：
Dalgas, U. [1 ]
Kant, M.
Stenager, E. [2 ]
机构：
[1] Univ Aarhus, Dept Sport Sci, DK-8000 Aarhus C, Denmark
[2] Univ So Denmark, Inst Reg Hlth Serv Res, Odense, Denmark
来源：
AKTUELLE NEUROLOGIE | 2010年 / 37卷 / 05期
关键词：
exercise therapy; strength training; fatigue; quality of life; rehabilitation; QUALITY-OF-LIFE; FUNCTIONAL-CAPACITY; GAIT KINEMATICS; EXERCISE; STRENGTH; PEOPLE; FATIGUE; RISK;
D O I：
10.1055/s-0030-1248526
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
This review summarises the existing knowledge regarding the effects of resistance training in patients suffering from relapsing-remitting multiple sclerosis (MS). Also, the literature concerning the effects of exercise on both the MS animal model and the immune system in MS patiente are reviewed. It is concluded that resistance training is a safe and beneficial exercise modality inmoderately impaired MS patients, potentially improving muscle strength, muscle mass, functional capacity, fatigue, mood and quality of life. Exercise may influence the disease progression in MS patients, but further studies are needed.
引用
收藏
页码：213 / 218
页数：6
相关论文
共 50 条
  • [41] Disability trajectories in relapsing-remitting multiple sclerosis
    Uher, T.
    Horakova, D.
    Havrdova, E. Kubala
    Izquierdo, G.
    Eichau, S.
    Patti, F.
    Prat, A. P.
    Girard, M.
    Duquette, P.
    Grammond, P.
    Onofrj, M.
    Lugaresi, A. L.
    Bergamaschi, R.
    Ozakbas, S.
    Grand'Maison, F.
    Hupperts, R.
    Sola, P.
    Ferraro, D.
    Sa, M. J.
    Kalincik, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 813 - 814
  • [42] Thalamic neurodegeneration in relapsing-remitting multiple sclerosis
    Wylezinska, M
    Cifelli, A
    Jezzard, P
    Palace, J
    Alecci, M
    Matthews, PM
    [J]. NEUROLOGY, 2003, 60 (12) : 1949 - 1954
  • [43] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S303 - S303
  • [44] Current management of relapsing-remitting multiple sclerosis
    Sedal, L.
    Wilson, I. B.
    McDonald, E. A.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 950 - 957
  • [45] Considerations in the treatment of relapsing-remitting multiple sclerosis
    Calabresi, PA
    [J]. NEUROLOGY, 2002, 58 (08) : S10 - S22
  • [46] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [47] Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis
    Scott, Lesley J.
    [J]. DRUGS, 2019, 79 (08) : 875 - 886
  • [48] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
    Marriott, James J.
    O'Connor, Paul W.
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 179 - 188
  • [49] Mycophenolate mofetil for relapsing-remitting multiple sclerosis
    Xiao, Yousheng
    Huang, Jianyi
    Luo, Hongye
    Wang, Jin
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (02):
  • [50] Ponesimod for the treatment of relapsing-remitting multiple sclerosis
    Gaber, Tarek A-Z K.
    Eltemamy, Marwa
    [J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2022, 26 (02) : 18 - 19
12345